
ADMA Biologics Faces Class Action Over Alleged Revenue Inflation
Investors in ADMA Biologics, Inc. are facing an August 10, 2026, deadline to join a securities class action lawsuit. The complaint alleges the company used channel stuffing to artificially inflate revenues for its specialty therapy ASCENIV, masking what may have been a 3% decline as 20% growth.





















